Verona Pharma plc                               

                          ("Verona Pharma" or the "Company")                       

                                   Notice of Results                               

    10 August 2016, Cardiff - Verona Pharma plc (AIM: VRP), the drug development
    company focused on first-in-class medicines to treat respiratory diseases,
    expects to announce its interim results for the six months ended 30 June 2016
    on Tuesday 13 September 2016.

                                        -Ends-                                     

    For further information please contact:

    Verona Pharma plc                        Tel: +44 (0)20 3283 4200                
                                                                                     
    Jan-Anders Karlsson, Chief Executive                                             
    Officer                                                                          
                                                                                     
    N+1 Singer                               Tel: +44 (0)20 7496 3000                
                                                                                     
    Aubrey Powell / Jen Boorer                                                       
                                                                                     
    FTI Consulting                           Tel: +44 (0)20 3727 1000                
                                                                                     
    Simon Conway / Stephanie Cuthbert /                                              
    Natalie Garland-Collins                                                          

    Notes to Editors

    About Verona Pharma plc

    Verona Pharma plc is a UK-based clinical stage biotech company focused on the
    development of innovative prescription medicines to treat respiratory diseases
    with significant unmet medical needs, such as chronic obstructive pulmonary
    disease (COPD), asthma and cystic fibrosis.

    Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in phase
    II trials as a nebulised maintenance treatment for COPD patients with moderate
    to severe disease and possibly as a treatment of acute exacerbations of COPD in
    the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor
    and therefore has both bronchodilator and anti-inflammatory effects, which are
    essential to the improvement of patients with COPD and asthma.

    Verona Pharma is also building a broader portfolio of RPL554-containing
    products to maximise its benefit to patients and its value. This includes the
    very significant markets for COPD and asthma maintenance therapy. The Company
    is also exploring the potential of the drug in different diseases, such as
    cystic fibrosis, where it is in pre-clinical testing and has recently received
    a Venture and Innovation Award from the Cystic Fibrosis Trust.